Skip to main content

Table 3 The specific characteristics and therapy efficacy of UABD nanomedicines

From: Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect

Nanomedicines Cavitation materials Drugs Particle size (nm) tumors Therapeutic effect Refs
Liposomal Doxorubicin MBs Doxorubicin 100 Glioma Survival time increased by 24% [120]
PEG-AuNPs Gold nanoparticle 50 [121]
MNBs NBs 500 [122]
TMZ−NB@PLN−AAp NBs Temozolomide 400.3 ± 4.7 Glioblastoma TIR: ~ 90% [123]
DOX-CLs Lipidosome
(MBs)
Doxorubicin ≈180 Glioma Survival extended to 81.2 days [124]
PTX-LIPO Lipidosome
(MBs)
Paclitaxel 98.3 Glioma Survival time increased by 20.8% [125]
Albumin-Gd-DTPA MBs Gd MR image enhancement; detect cerebral hemorrhage [126]
Lipidosome-doxorubicin Lipidosome
(MBs)
Doxorubicin ≈100 Glioma [127]
LPHNspCas9/MGMT-cRGD MBs CRISPR/Cas9 179.6 ± 44.82 Glioma Inhibit tumor growth and prolong the survival time of tumor-bearing mice [128]
OFP and DFB droplets PFCNDs Proteins 171 /183 Successful delivery of 40 kDa dextran [129]
Cationic nanodroplets PFCNDs Gene 300–400 Gene transfection efficiency was enhanced 14-fold on HepG2 cells [130]
Acoustically-activated nanodroplets PFCNDs Dextran 200–300 Up to 33% of the animals showed a fluorescence enhancement [44]